Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_assertion type Assertion NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_head.
- NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_assertion description "[Collectively, our data indicate that ERBB2-mediated breast cancer progression requires ?-catenin signaling and can be therapeutically targeted by selective ?-catenin/CBP inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_provenance.
- NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_assertion evidence source_evidence_literature NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_provenance.
- NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_assertion SIO_000772 23720052 NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_provenance.
- NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_assertion wasDerivedFrom befree-2016 NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_provenance.
- NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_assertion wasGeneratedBy ECO_0000203 NP1081801.RAjylmL-NmUKppCz45m-mVnpo62K4br74Xp7KZ0Xs8yfw130_provenance.